MY ABPI LOGIN
 
Tags - UK and EU future relationship

Manifesto for a strong UK economy outside the EU

The ABPI is calling on the UK’s political leaders to ensure that the roadmap for the UK leaving the EU secures the future of our country’s pharmaceutical industry.

Maintaining and growing the UK’s world leading Life Sciences sector in the context of leaving the EU

The following Executive Summary two page report and the detailed report - capture the positive approach and can do attitude of all participants and reflect the desire to make a success of the opportunities ahead of us. It’s a record of a snapshot in time of our developing thinking rather than as a...

Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market

This OHE Consulting report, prepared for the ABPI and the BioIndustry Association, explores the consequences of the exit of the United Kingdom and from the European Union on public health in the UK and in the EU. It also provides an estimate of the economic impact for pharmaceutical companies.

UK’s Exit from the European Union: Brexit Life Science Industry Coalition Position Paper

A joint policy document on the potential impact of the United Kingdom’s exit from the European Union from eleven associations representing the European and British life science industry, including the ABPI.

Brexit and the impact on patient access to medicines and medical technologies

The UK’s plans to leave the European Union (EU) and the EU’s single market could have serious implications for patients’ access to medicines and medical technologies.

This briefing explores how UK and EU citizens could be affected by the disruption in trade that could result from the UK’s exit from...

UK Clinical Research Post Brexit

In a week that sees the MHRA and CRUK publish critical information about the UK’s clinical research environment post-Brexit, ABPI's Deputy Chief Scientific Officer Dr Sheuli Porkess explores what it means for the pharmaceutical industry.

Industry response to Simon Stevens’ comments on the Andrew Marr show

Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.

New verification system will secure patient safety and support continuation of medicines supply

UK Marketing Authorisation Holders urged to register with SecurMed UK

ABPI and BIA input to MHRA consultation on EU Exit 'no deal' contingency legislation for the regulation of medicines and medical devices

The ABPI and BIA have submitted a joint submission in response to the MHRA and DHSC consultation on 'no deal' contingency legislation for medicines and devices regulation for the UK.

Pharmaceutical industry responds to Trade Bill amendment on medicines

Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.

Pharmaceutical industry reaction to Brexit White Paper

The UK government have today published a White Paper detailing their position on ‘The Future Relationship between the United Kingdom and the European Union’.
;